JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Multicenter, Randomized, Controlled, Open-label Phase III Clinical Trial Evaluating the Efficacy and Safety of JS107 in Combination With Toripalimab and Chemotherapy Versus Sintilimab in Combination With Chemotherapy as First-line Treatment for CLDN18.2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a multicenter, randomized, open-label, controlled Phase III clinical trial aimed at evaluating the efficacy and safety of JS107 combined with toripalimab XELOX versus sintilimab combined with XELOX as first-line treatment for patients with advanced G/GEJ adenocarcinoma.
The research subjects were patients with unresectable locally advanced, recurrent or metastatic G/GEJ adenocarcinoma who were CLDN18.2-positive and HER2-negative and had not received systemic treatment before (except for neoadjuvant/adjuvant therapy that occurred more than 6 months after disease progression/recurrence from the last treatment). The study took BICR-PFS and OS as Dual primary endpoints.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Bifeng Liu
- 电话号码:021-61058800
- 邮箱:bifeng_liu@junshipharma.com
研究联系人备份
- 姓名:Junliang Li
- 邮箱:Junliang_li@junshipharma.com
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 招聘中
- Sun Yat-sen University Cancer Center
-
接触:
- Ruihua Xu, PhD
- 电话号码:18758246502
- 邮箱:xurh@sysucc.org.cn
-
首席研究员:
- Ruihua Xu, Ph.D
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria
- The patient voluntarily participated, provided informed consent, signed a written informed consent form, and had good compliance.
- Age ≥18 years (including), male and female. 3)Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4)Expected survival period ≥3 months.
5)Patients with HER2-negative, unresectable locally advanced, recurrent, or Metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed by histology/cytology. 6)Previously untreated for systemic therapy for locally advanced, recurrent, or Metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. 7)Positive for CLDN18.2 by IHC testing at the central laboratory. 8)According to the RECIST v1.1 criteria, the patient has ≥1 measurable lesion. 9)The functional level of the organ meets the requirements of the protocol. 10)Agree to use contraception during the study period; females of reproductive potential will undergo a blood pregnancy test within 7 days prior to randomization, with a negative result.
Exclusion Criteria:
- Previously received any drug or cell therapy targeting CLDN18.2
- Received major surgery, live vaccine administration, or Drug therapy with other investigational medicinal products, or received radiotherapy within 2 weeks prior to randomization.
- Imaging shows cerebral tumor lesions (unless whole-brain radiotherapy or surgery, etc., local treatment has been completed, and imaging and clinical stability have been assessed according to the protocol) 4)Peripheral neuropathy ≥ Grade 2
5)Idiopathic pulmonary fibrosis, Organising pneumonia, drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia on screening chest computerised tomography (CT) scan 6)Pericardial effusion, Pleural effusion, or ascites with a large volume, or with clinical symptoms, or requiring symptomatic treatment.
7)There is a need for systemic antimicrobial or antiviral therapy for active infection.
8)Subjects who cannot take oral medications, require enteral nutrition to maintain feeding, or have Malabsorption syndrome or other conditions affecting gastrointestinal Malabsorption.
9)Presence of biliary or gastrointestinal obstruction, or persistent recurrent vomiting 10)Weight loss of >10% within the previous 2 months or severe Malnutrition, known prior to randomization.
11)History of gastrointestinal perforation and/or fistula within the prior 6 months; presence of high-risk Haemorrhage of digestive tract disease or risk of rupture bleeding or gastrointestinal/respiratory fistula 12)Serious cardiovascular and cerebrovascular diseases 13)History of systemic treatment for autoimmune diseases within the past 2 years 14)Randomly selected patients with any other Neoplasm malignant within the past 5 years.
15)Known severe allergic reaction to any ingredient in the study drug formulation 16)Known active Hepatitis B, active Hepatitis C, human immunodeficiency (HIV) infection, or have undergone allogeneic stem cell or Solid organ transplant.
17)Diseases determined by researchers to be unsuitable for participation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:JS107 in combination with Toripalimab and XELOX Chemotherapy
|
JS107: 2 mg/kg on day 1 Q3W; Toripalimab (T): 240 mg on day 1 Q3W.
Capecitabine (C): 750 mg/m² BID Day1-Day14, Q3W,Oxaliplatin 100mg/m² on Day1 Q3W, Maximum of 6 cycles.
|
|
有源比较器:Sintilimab in combination with XELOX Chemotherapy
|
Sintilimab: 3 mg/kg or 200 mg Day1 Q3W, Capecitabine: 1000 mg/m² BID Day1-Day14, Q3W,Oxaliplatin 130mg/m² on Day1 Q3W, Maximum of 6 cycles.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
BICR-PFS
大体时间:最长2年
|
基于盲态独立中心审查(BICR)评估的无进展生存期(BICR-PFS)(根据RECIST v1.1标准)
|
最长2年
|
|
总生存期
大体时间:最长5年
|
这项多中心、随机、开放标签的III期研究的主要终点为总生存期(OS),定义为从随机化至任何原因所致死亡的时间,旨在比较JS107与研究者选择疗法在CLDN18.2阳性、HER2阴性晚期胃或胃食管结合部腺癌患者中的获益,这些患者既往至少接受过一线系统性治疗。
|
最长5年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
INV-PFS
大体时间:最多2年
|
研究者评估的无进展生存期(INV-PFS,根据RECIST v1.1标准)
|
最多2年
|
|
BICR-ORR 或 INV-ORR
大体时间:长达2年
|
由研究者或BICR评估的ORR(根据RECIST v1.1标准)
|
长达2年
|
|
BICR-DCR 或 INV -DCR
大体时间:长达2年
|
由研究者评估的无进展生存期(INV-PFS,根据RECIST v1.1标准)
|
长达2年
|
|
BICR-缓解持续时间或研究者评估-缓解持续时间
大体时间:长达2年
|
研究者或BICR根据RECIST v1.1标准评估的DoR
|
长达2年
|
|
不良事件的发生率与严重程度
大体时间:最多2年
|
根据NCI-CTC AE v5.0标准评估的不良事件(AEs)发生率和严重程度
|
最多2年
|
|
JS107的谷浓度
大体时间:长达2年
|
JS107的谷浓度(包括ADC、总抗体和毒素)
|
长达2年
|
|
JS107中和抗体(NAb)的发生率
大体时间:最长2年
|
JS107中和抗体(NAb)发生率(包括ADC、总抗体和毒素)
|
最长2年
|
|
Anti-drug antibodies (ADA) for JS107
大体时间:up to 2 years
|
Incidence and titer of anti-drug antibodies (ADA) for JS107 (including ADC, total antibody, and toxin)
|
up to 2 years
|
|
Blood trough concentration of toripalimab
大体时间:up to 2 years
|
To evaluate the blood trough concentration of toripalimab
|
up to 2 years
|
|
Immunogenicity of toripalimab
大体时间:up to 2 years
|
Incidence and titer of anti-drug antibody (ADA) of toripalimab,
|
up to 2 years
|
|
Incidence of neutralizing antibodies (NAb) to Toripalimab
大体时间:up to 2 years
|
ADA-positive samples for the presence of Neutralising antibodies (Nab).
|
up to 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- JS107-004-III-GC
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.